A proteomic atlas of glypican‐3 interacting partners: Identification of alpha‐fetoprotein and other extracellular proteins as potential immunotherapy targets in liver cancer
Proteoglycan Research · 2024
DOI: 10.1002/pgr2.70004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proteoglycan Research, 2024. Verfasst von Yi-Fan Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Intramural NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Antibody and cell‐based therapeutics targeting cell surface receptors have emerged as a major class of immune therapeutics for treating cancer. However, the number of cell surface targets for cancer immunotherapy remains limited. Glypican‐3 (GPC3) is a cell surface proteoglycan and an oncofetal antigen. In this study, we report a large‐scale tumor‐associated GPC3 co‐immunoprecipitation‐proteomic study using liver cancer xenograft tumors in mice. We identified 153 GPC3‐associated proteins through mass spectrometry. To identify potential drug targets, we categorized GPC3‐associated proteins based on their subcellular locations using UniProt annotations, with a focus on extracellular proteins. Additionally, we annotated differentially expressed proteins in hepatocellular carcinoma versus nontumor liver samples based on the literature, analyzed expression levels in tumor versus normal tissues using TCGA and GTEx databases via GEPIA, and identified prognostic liver cancer markers according to GEPIA. Among GPC3‐associated proteins, immunoglobulin superfamily member 1, alpha‐fetoprotein (AFP), FAT atypical cadherin 1, formin 1, and guanylate cyclase 2 C, were identified as potential therapeutic targets. Furthermore, we validated the direct protein interaction between GPC3 and AFP through immunoprecipitation with purified proteins and through co‐localization imaging using immunofluorescence microscopy. This study provides large proteomic datasets related to GPC3‐associated proteins, enhancing our understanding of glypican biology in cancer cells and offering a new approach to identifying immunotherapy targets.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA.
- Laboratory of Proteomics and Analytical Technologies, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702, USA.
Förderung
- NCI NIH HHS
- Intramural NIH HHS
- National Cancer Institute
- U.S. Department of Health and Human Services
Zitieren
APA
Zhang, Y. F., Lin, S., Zhen, X., & Ho, M. (2024). A proteomic atlas of glypican‐3 interacting partners: Identification of alpha‐fetoprotein and other extracellular proteins as potential immunotherapy targets in liver cancer. Proteoglycan Research. https://doi.org/10.1002/pgr2.70004
Vancouver
Zhang YF, Lin S, Zhen X, Ho M. A proteomic atlas of glypican‐3 interacting partners: Identification of alpha‐fetoprotein and other extracellular proteins as potential immunotherapy targets in liver cancer. Proteoglycan Research. 2024. doi:10.1002/pgr2.70004
BibTeX
@article{Zhang2024,
author = {Zhang, Yi-Fan and Lin, Shaoli and Zhen, Xiao and Ho, Mitchell},
title = {A proteomic atlas of glypican‐3 interacting partners: Identification of alpha‐fetoprotein and other extracellular proteins as potential immunotherapy targets in liver cancer},
journal = {Proteoglycan Research},
year = {2024},
doi = {10.1002/pgr2.70004}
}
EUVIMED